2Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol, 1993,11:1024-1032.
3Hvizdala EV, Berard C, Callihan T, et al. Nonlymphoblastic lymphoma in children-histology and stage-related response to therapy: a Pediatric Oncology Group study. J Clin Oncol, 1991,9:1189-1195.
4Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy:a report of the Berlin-Frankfurt-Munster Group trial NHL-BFM90.Blood, 1999,94: 3294-3306.
5Patte C, Auperin A, Michon J, et al. The Societe Francaise d' Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood,2001,97:3370-3379.
6Klumb CE, Schramm MT, de Resende LM, et al. Treatment of children with B-cell Non-Hodgkin's lymphoma in developing countries:the experience of a single center in Brazil. J Pediatr Hematol Oncol,2004, 26:462-468.
7Chantada GL, Felice MS, Zubizarreta PA, et al. Results of a BFM-based protocol for the treatment of childhood B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukemia in Argentina. Med Pediatr Oncol, 1997,28:333-341.
8Kavan P, Kabickova E, Gajdos P,et al. Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM 90 protocols. Pediatr Hematol Oncol, 1999, 16:201-212.
9Link MP, Shuster J J, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med, 1997, 337:1259-1266.
10Gerrard M, Cairo M, Weston C, et al. Results of the FAB international study in children and adolescents ( C + A) with localised, resected B cell lymphoma (large cell [LCL] [ C]. Burkitt [ BL] and Burkitt-like [ BLL] ). Chicago: ASCO, 2003. Abstract No: 3197.
10Moricke A, Reiter A, Zimmermann M, etal. Risk - adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unseleeted pediatric and adoleseent patients enrolled in the trial ALL - BFM 95 [ J ]. Blood, 2008, 111(9) :4477 -4489.
